Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $83.2 million.

  • Abeona Therapeutics' Cash & Equivalents rose 41806.52% to $83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.2 million, marking a year-over-year increase of 41806.52%. This contributed to the annual value of $23.7 million for FY2024, which is 5998.24% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Cash & Equivalents stood at $83.2 million, which was up 41806.52% from $163.9 million recorded in Q2 2025.
  • Abeona Therapeutics' Cash & Equivalents' 5-year high stood at $163.9 million during Q2 2025, with a 5-year trough of $5.0 million in Q1 2023.
  • Over the past 5 years, Abeona Therapeutics' median Cash & Equivalents value was $17.9 million (recorded in 2024), while the average stood at $34.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 43129.15% in 2021, then tumbled by 8085.97% in 2023.
  • Over the past 5 years, Abeona Therapeutics' Cash & Equivalents (Quarter) stood at $38.8 million in 2021, then crashed by 62.52% to $14.6 million in 2022, then increased by 1.76% to $14.8 million in 2023, then skyrocketed by 59.98% to $23.7 million in 2024, then soared by 251.22% to $83.2 million in 2025.
  • Its last three reported values are $83.2 million in Q3 2025, $163.9 million for Q2 2025, and $84.5 million during Q1 2025.